DM Clinical debuts Boston site, will begin enrollment for Moderna trial

DM Clinical Research has opened the doors to its first trial site in the Boston area and will begin recruiting for Moderna’s cytomegalovirus (CMV) vaccine study. 

Houston-based DM Clinical’s newest facility is located in the Boston suburb of Brookline and is housed in a 4,000-square-foot space that includes patient rooms, laboratory facilities, and vaccine storage and preparation rooms, the company said in a Jan. 19 press release.

“The Boston site enhances our ability to offer research sponsors access to a diverse patient footprint that already includes underserved communities in Chicago, Detroit, Houston and Philadelphia,” Mohammad Millwala, DM’s founder and chief executive, said in the release.

Jose Azocar, M.D., Ph.D., an internal medicine specialist with more than three decades of clinical research experience, was named the lead principal investigator at the Boston site, and Amy Sheets will served as regional director.

DM Clinical, which was founded in 2006, boasts 13 dedicated research centers and a network of affiliate sites.

The CMVictory trial will feature Moderna's investigational vaccine mRNA-1647, which is designed to help the immune system protect against CMV. The virus is related to those that cause chickenpox, herpes simplex and mononucleosis.